The Medtech Innovation Podcast

I'm joined by Lorenzo Johnson, Founder & CEO of Icovy Marketing — one of the only agencies built from the ground up for medtech — as we break down why so many companies with genuinely great technology still struggle to win commercially, how AI rewired buyer behavior and discoverability, and why marketing deserves to be treated as an investment instead of an expense.

Why Great Tech Still Loses Commercially
→ "It's never been cheaper to look qualified" — AI gives everyone access to the same polished messaging, so baseline competence is no longer a differentiator
→ The companies winning aren't the ones with the best widget, they're the ones who differentiate and actually get discovered
→ Traditional medtech go-to-market built on trade shows and relationships is being disrupted by a digital-first buyer

Prime the Market Before You Launch
→ Don't wait for FDA clearance to start marketing — educate and prime your environment early so you're not flipping a switch on launch day
→ Case in point: a practicing neurosurgeon-CEO posting clinical content weekly for ~2.5 years pre-clearance, building an audience that's roughly 25% surgeons
→ You can't buy that kind of credibility — it's earned trust compounded over time

Own Your Audience
→ "If LinkedIn went away tomorrow, you'd lose your entire audience" — your followers live on a platform you don't control
→ Build systems to pull that audience into your own database
→ Get clear upfront: is this an awareness play or actual lead gen? They are not the same spend

The Truth About Trade Shows, Blasts, and Banners
→ Trade shows run $10K–$100K+ a show with variable lead quality and weak attribution
→ Association email blasts and banner ads are often "selling impressions and a hope and a dream that someone's going to click"
→ Event sponsorships are awareness only — Lorenzo would rather own a tiny room of perfect-fit people than be a small logo in a hallway

AI Changed Discoverability Forever
→ Buyers now research in ChatGPT, Claude, and Gemini first — "it's another layer of SEO, just deeper"
→ Ignore it and "you're losing digital real estate and opportunities without even knowing they exist"
→ AEO and GEO (optimizing for AI answer engines) reward long-form, specific, citable, technically transparent content

Stop Hiding Your Secret Sauce
→ Walk any trade show floor and you'll see "the same freaking buzzwords on everybody's booth" — quality, speed, centers of excellence
→ CDMOs especially default to stealth mode, but digitally you have to show your cards to get cited
→ The taxes-and-housing analogy: if you never flex what you actually do, don't expect to qualify when it counts

Marketing Is an Investment, Not a Line Item
→ "If you think marketing is an expense, you're going to feel it in the next five to ten years" as competitors take market share
→ Marketing has long carried a softer hue than sales, but sales can't close buyers who don't know you exist
→ Done right, the digital engine works 24/7 and can 2–4x your inbound

This Doesn't Replace Relationships — It Protects Them
→ Relationship-driven sales got plenty of companies to $10–$50M, but that organic pipeline can quietly dry up
→ When a shock hits — a recession, a COVID-style loss of hospital access — a kinked relationship base leaves you exposed
→ Digital is the insurance policy and the multiplier, feeding the machine while you sleep

The Next Five Years
→ Buyers will self-educate through AI before they ever talk to you, so feed those engines your own content and perspective
→ "People are not going to fall for BS like they used to" — transparency and conviction win
→ Repetition still matters: it takes 7–11 touch points before someone buys, and most companies quit way too early

Best Quotes:

"It's never been cheaper to look qualified."

"We're now building systems for not only humans, but we're building systems for machines as well."

"If you're thinking that marketing is an expense, I think you're going to be feeling it in the next five to ten years when you're seeing people start leaping ahead of you and you're losing market share."

"If you're not focusing on it, you're losing digital real estate. You're losing opportunities without you even knowing that they're there."

Want more insights on medtech innovation?
Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

Want real CDMO sales intelligence that grows revenue without growing headcount?
Check out Campaigns

Find the perfect vendors for your medtech project for free at MedtechVendors

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND LORENZO JOHNSON ON SOCIAL
Lorenzo's LinkedIn - https://www.linkedin.com/in/lorenzo-johnson/
Icovy Marketing - https://www.icovy.com/

Episode Timestamps (approximate — adjust to final edit):
0:00 - Intro: Lorenzo Johnson and Icovy Marketing, a medtech-first agency
3:00 - Why great-tech companies still lose commercially in the AI era
7:30 - "It's never been cheaper to look qualified" and the AI-slop problem
12:00 - Priming the market early and the neurosurgeon-CEO case study
17:00 - Owning your audience instead of renting it on LinkedIn
22:00 - Rapid-fire: trade shows, association blasts, banners, sponsorships
29:00 - AI and the new layer of discoverability (SEO, AEO, GEO)
35:00 - Stop hiding your secret sauce: the CDMO buzzword trap
41:00 - Marketing is an investment, not a line item
47:00 - Why digital complements relationships instead of replacing them
53:00 - The next five years of medtech commercialization

I'm joined by Ryan Schoonmaker, Founder & CEO at Tight Line Solutions, as we explore why growth-stage medtech teams burn out fixing past shortcuts, the two-roadmap discipline almost nobody actually runs, and how to lead engineering through five-alarm fires without breaking your team.

In this episode, we dive deep into:
Why "Tight Line" Is the Right Mental Model for Product Development
→ Ryan named the company after fly fishing — keeping the right line tension is the instinct great engineering leaders have
→ Too much tension snaps the team, too little and the program gets away
→ That nascent expectation level inside a team is rarely written down but drives everything

Cutting Your Teeth at Helbling and Dexcom
→ Weekly client work at Helbling forced Ryan to communicate engineering decisions, not just make them
→ Dexcom G6 and G7 taught him that wearable medtech lives or dies on integration points between hardware, firmware, software, and human factors
→ "Killer questions" like battery size or PCB footprint can flip your entire architecture if you don't surface them early

The Two-Roadmap Playbook Most Growth-Stage Medtech Misses
→ Run an iterative roadmap on the product just launched AND a separate technology roadmap five years out
→ Biggest misstep: putting unproven technology into V1 instead of shipping fast and learning from users
→ V1 should generate revenue, expose failure modes, and feed Gen 2 — trying to make V1 perfect kills companies

The Stairstep Regulatory Strategy Sophisticated Founders Use
→ Get something cleared, then use it as your own predicate via special 510(k) or letter to file
→ While FDA reviews your initial submission, your team iterates Gen 2 in parallel
→ Ryan's seen this used to dodge a de novo pathway when one feature would have triggered it

Don't System-Architect Yourself Out of Cost Reductions
→ Most teams assume they'll automate their way to better COGS later — a $750K assembly cell and a year of capex
→ A smarter Gen 2 with fewer components and a cleaner architecture beats automation alone
→ Design Gen 1 so cost-down doesn't require a complete redesign — that's the trap that kills margin

Where Growth-Stage Companies Actually Break
→ Moving from low-cavity to high-cavity molds introduces variability that wrecks downstream bonding and welding
→ A 5% process difference when switching suppliers is enough to detonate a launch
→ Identify what's "new, unique, and difficult" upfront and characterize those subsystems deeply before scaling

Tech Debt Is Real in Hardware
→ Hardware debt costs more to fix later than to implement now — exactly like financial debt accruing interest
→ Pay it down on a "payment plan" via your Gen 2 roadmap, not by ignoring it

Best Quotes:

"You want to keep the line tight. Too much tension is going to break. Too little tension, you're going to lose the fish."

"The misstep that a lot of companies make is they try to put new technology in their products too early."

"The key is to not system-architect yourself out of cost reductions."

"Where are the gremlins hiding? Because they're always there. Let's go out and find them."

Want more insights on medtech innovation?
Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND RYAN SCHOONMAKER ON SOCIAL
Ryan's LinkedIn - https://www.linkedin.com/in/ryan-schoonmaker-59048411/
Ryan's Substack - https://substack.com/@ryanschoonmaker
Tight Line Solutions Free Technical Risk Launch Scan - https://stan.store/ryanschoonmaker/p/free60-minutes

Episode Timestamps:
0:00 - Intro and the "Tight Line" mental model
5:00 - Career roots: Helbling, Dexcom, and wearable integration points
11:00 - When to start designing Gen 2 (when you submit Gen 1 to FDA)
17:00 - The COGS trap and cost-reduction architecture
22:00 - Stairstep regulatory strategy and using yourself as your own predicate
29:00 - Why Ryan started Tight Line
32:00 - Growth-stage pitfalls: scale, suppliers, and hidden cliffs
46:00 - Technical debt in hardware and how interest accrues
58:00 - Leadership in a crisis: pulling teams out and driving clarity
1:00:00 - The joy of engineering and authentic leadership

I'm joined by Lindsay Crescenzo, R&D Director at Heraeus, as we explore how contract manufacturers are powering the electrophysiology boom, the strategic logic behind selective automation investments, and what it actually takes to build a high-performing engineering team from scratch.

In this episode, we dive deep into:
The DNA of Heraeus: Contract Manufacturing for EP
→ Heraeus focuses exclusively on contract manufacturing and design support without developing competing products — from process development through commercialization
→ Heavy investment in their Costa Rica facility for scaled catheter production, with a customer mix spanning large OEMs and strategic startups
→ How they evaluate which programs to take on and the capabilities that make them worth the conversation

Why Large OEMs Send Programs Outside
→ The three core reasons OEMs go external: keeping their internal pipeline moving, cost optimization, and launching programs they can't otherwise resource
→ Contract manufacturers must be faster, bring space the OEM doesn't have, and match technical depth — or they don't add real value
→ How Heraeus approaches large OEM relationships by forward-investing in automation and team capacity before the ask

Clinical Immersion: Engineers in the Cath Lab
→ Heraeus sends engineers to observe live procedures and interact directly with physicians — most engineers designing EP devices have never seen one used
→ Understanding real physician workflow and patient need produces better device designers, full stop
→ Clinical immersion closes the gap between engineering specs and what actually works at the table

Automating Bottlenecks, Not Full Lines
→ Heraeus targets only the constraint steps in manufacturing for automation — not attempting to automate entire production lines
→ Investment focus: robotics and laser systems that serve multiple products across multiple customers
→ The decision framework weighs labor cost, operator ergonomics, and margin improvement — not just what's technically possible

The PFA Race and EP Catheter Innovation
→ Electrophysiology is growing double-digit with every major customer running hard on Pulse Field Ablation
→ Key engineering challenges: optimizing flex circuits, microelectronics, and high-voltage delivery in increasingly compact form factors
→ Companies are merging capabilities into single catheters — space optimization is the defining engineering constraint

Reimbursement as a Design Input
→ Reimbursement has to be in the room during design — not something you revisit after submission
→ The real value driver isn't a better mousetrap for existing procedures — it's expanding which patients physicians can treat
→ 40 million AFib patients worldwide. Only 6% are getting treatment. That's the actual opportunity.

Hiring Philosophy: Filter First, Then Find Good People
→ Lindsay's three non-negotiables: no arrogance, no selfishness, no drama — screen those out before anything else
→ Hire before you win the program, not after — having the right people in place when the contract lands changes everything
→ Building from 2 to 150 engineers required asking the right questions early and narrowing quickly to candidates who fit both sides

Best Quotes:
"There are 40 million people in the world that need treatment and only 6% of them are getting treatment."

"I don't like arrogance or selfishness or drama. I sort those out. Then you just look for the good people."

"If you're not sure what programs are going to hit, having the people in place is going to make a huge difference rather than waiting until you win the program."

"AI is going to significantly help us with engineering - not by reinventing things, but by helping us move faster."

Want more insights on medtech innovation?
Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. 
Join for free using this link - https://xo-medtech.circle.so/XO-medtech-pricing-page

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn — https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn — https://www.linkedin.com/company/xo-medtech/

FIND LINDSAY CRESCENZO ON SOCIAL
Lindsay's LinkedIn — https://www.linkedin.com/in/lindsay-crescenzo-mba-mdi-07797945/
Heraeus Website — https://www.heraeus.com/

Episode Timestamps:
0:00 - Introduction to Lindsay Crescenzo and Heraeus
2:54 - The DNA of Heraeus: Contract Manufacturing and Design Support
3:34 - Transitioning from Medtronic OEM to Contract Manufacturing
5:06 - Career Advice: Diversifying Skills Across Clinical Verticals
9:10 - Clinical Immersion: Sending Engineers into the Cath Lab
10:11 - Why Large OEMs Outsource Engineering and Manufacturing
16:06 - Connecting R&D Engineering with Sales and Marketing Teams
22:42 - Automating Bottlenecks, Not Full Lines
30:20 - Design Changes Between Clinical Trial Phases
33:41 - EP Catheter Innovation: Flex Circuits and Microelectronics
37:52 - Reimbursement as a Device Design Constraint
41:59 - AI Integration in Development and Manufacturing
48:40 - Hiring Philosophy: No Arrogance, Selfishness, or Drama
52:07 - Career Advice for Young Engineers

I'm joined by Brian Carlisle, Managing Partner and Founder of Carlisle Strategic Partners, as we explore how to build predictable sales engines in medtech, manage distributor relationships like direct reps, and navigate the capital raising landscape without leaving money on the table.

Building a Predictable Sales Engine: The Buying Process Mirror
→ Brian deployed a customized sales methodology at Integra across a $500M+ division, doubling profitability at Permapure within two years using the same framework
→ The core concept: map your customer's buying process first, then build your sales process to mirror each step with corresponding seller and customer action commitments
→ Interview eight types of buying influences - from surgeons to supply chain heads - to understand how decisions actually get made
→ The middle 60% of your sales team becomes dramatically more effective when they have a repeatable roadmap instead of relying on gut feel

The Independent Rep Playbook: Treating 1099s Like W-2s
→ Most companies just send a contract and commission check to distributors - Brian calls this "extremely ineffective" after 18+ years as an operator
→ Ride shotgun with your independent reps in their territory and ask "how can we help you win?" instead of beating them down on quotas
→ Give distributors quotas, incentive plans, and recognition just like direct reps - most companies give indirects zero targets and get passive results
→ Include independent reps on team calls and strategic planning - managed right, there's no reason they can't perform like a direct rep

Sales Leadership: The Bi-Weekly Rhythm That Drives Results
→ Brian held bi-weekly one-on-ones with every team member, spending an hour per person walking through their territory through a lens of "how can I help you?"
→ The payoff: when it's the last day of the quarter and your rep is 20% over quota with a tee time, they'll still make that extra call because you built the relationship
→ Avoid "shiny object syndrome" - make evolutionary changes annually and stop changing messaging every six weeks, which creates whiplash across the sales force

From Operator to Advisor: The Carlisle Strategic Partners Model
→ Brian's combined buy-side M&A experience at Integra and Halma plus deep operator experience is what differentiates his advisory approach
→ Built a proprietary commercial scoring tool for companies under $50M that would otherwise need McKinsey to assess their commercial readiness
→ Firm rule: if someone doesn't add strategic value to the board, they shouldn't be on it - every cap table addition should bring more than a check

Capital Raising: Don't Lead With Your Valuation
→ Never put a valuation on your ask slide - stating "we're raising $30M at a $50M pre" creates questions that cause investors to tune out the rest of the story
→ Be crystal clear on three things: how much you need, the value creation plan, and the timeline to execution
→ The capital environment is improving (2025 better than 2024, 2026 trending better) but expect longer timelines - diligence alone can take three months

Pitch Deck Mastery: Using AI to Refine Your Raise
→ Brian's team uploads investor call recordings to AI tools that audit what went well and what needs improvement
→ The pitch deck will never be "done" - accept that and constantly refine based on real investor feedback, not internal assumptions
→ Most decks are 40 slides with too many words - get to the point and let the data speak for itself

Best Quotes:
"If somebody doesn't add strategic value on the board, they shouldn't be on the board."

"Your sales process should mirror your customer's buying process. When you institutionalize this, your middle 60% becomes as effective as your top 20%."

"These aren't people that you just contract and send them a commission check and they're going to do what you need them to do. That's extremely ineffective."

"The pitch deck will never be done. Just accept that. But if you can get the messaging right and let the data speak for itself, you can typically be successful."

Want more insights on medtech innovation?
Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND BRIAN CARLISLE ON SOCIAL
Brian Carlisle's LinkedIn - https://www.linkedin.com/in/brian-carlisle
Carlisle Strategic Partners Website - https://carlislestrategic.com

Episode Timestamps:
0:00 - Introduction to Brian Carlisle and Carlisle Strategic Partners
1:24 - Brian's Career Journey: From Biomed Orthopedics to CEO
4:33 - The Evolution From Sales Leader to C-Suite Operator
8:32 - The Value of an MBA and Building a Mentor Network
14:18 - Building a Predictable Sales Process That Mirrors the Buyer
19:20 - How to Map Customer Buying Processes Across Different Call Points
22:00 - Managing Independent Reps and Distributor Groups Effectively
27:56 - Sales Communication Cadence: The Bi-Weekly Rhythm
30:30 - Avoiding Shiny Object Syndrome in Sales Strategy
35:35 - Arming Your Sales Team With the Right Collateral
39:29 - Targeting and Account Focus for Early-Stage Companies
42:40 - Carlisle Strategic Partners: The Operator-Investor Advisory Model
46:46 - The Current Capital Markets Landscape for Medtech
56:46 - Capital Raising Strategy: Don't Lead With Valuation
1:11:34 - The Ask Slide: How to Present Your Raise
1:14:00 - Using AI to Refine Investor Pitch Decks

I'm joined by Rhys Williams, CEO at Orchestrate, as we explore how AI-powered regulatory technology is breaking down the barriers to medtech commercialization and why the infrastructure gap — not the science — is what's really holding the industry back.

The $50K Barrier Nobody Questions
→ Medtech companies are told to budget $20,000-$50,000 minimum just for regulatory clarity — Rhys challenges this accepted cost as a solvable infrastructure problem, not a necessary expense
→ The real cost isn't government fees — it's labor hours, quarterly billing cycles, and documentation overhead that compound into six-figure regulatory bills before a single submission is filed
→ Companies that delay regulatory work until post-development discover expensive gaps in clinical data demographics that force costly retreats to data collection

Why Paper-Based Systems Aren't Actually the Problem
→ Regulatory affairs professionals don't love paper-based processes — they use them because they're robust, auditable, and proven to maintain safety standards across decades of use
→ Intentional friction in the product development process serves a purpose — the goal isn't zero friction, it's eliminating the friction that doesn't serve safety or quality
→ The real breakdown happens when formal processes force people out of their natural workflow, creating workarounds and local version deviations that actually undermine compliance

Orchestrate: RegTech That Lives in Your Existing Tools
→ Deep integration with Microsoft Office and Google Workspace means regulatory workflows live inside Word, Teams, and Google Docs — not another dedicated platform that requires a learning curve
→ The platform analyzes existing certifications and documentation to show exactly what can be reused for new market expansion, generating 16+ page submission documents in clicks
→ What would have taken hours of manual document prep can now be done in seconds by parsing, chunking, and reusing your existing regulatory documentation

Building an AI-Native QMS from Scratch
→ Rather than layering features onto legacy QMS platforms, Orchestrate reimagined quality management starting from document storage with change management and building up
→ Automated workflows trigger change management, review, and approval processes the moment a document is modified — configurable per product, region, or company
→ Dedicated auditor accounts with full immutable action logs solve the "what happens when the auditor arrives" anxiety that plagues every medtech team

The RegTech Founder's "If Not Me, Then Who" Mindset
→ Rhys's career thread from medical physics at UCL to prosthetics research to Meta advertising automation created a rare Venn diagram of health, computer science, and commercialization expertise
→ Running a Pan-Africa disability innovation accelerator forced him to formalize what companies actually need to know to commercialize — building the philosophical foundation for Orchestrate
→ While clinical trials and CROs receive heavy VC attention, regulatory infrastructure remains a greenfield opportunity that most builders have overlooked

Team Building When AI Changes the Rules
→ The bottleneck has shifted from "can you build it" to "should you build it" — domain expertise and knowing what to build is now more valuable than raw engineering capacity
→ AI coding assistants are like the most eager intern you've ever had — they'll move your button AND redesign your entire nav bar unless you maintain specificity and discipline
→ Orchestrate is hiring regulatory affairs professionals before additional engineers, building the domain expertise feedback loop first

The Banking Parallel That Predicts MedTech's Future
→ UK banking went from three-to-five day paper-based money transfers to 30-second automated transactions — the same transformation is possible in medtech regulatory processes
→ Legal frameworks around AI-augmented human judgment need to evolve first — once they do, Rhys predicts a "penny falls" cascade of rapid change across the industry
→ AI-first notified bodies like Scarlett and semi-automated testing labs could compress biocompatibility report timelines from months to weeks

Best Quotes:

"I can build an innovative med product or I can accelerate all med products."

"If not me, then who? Because someone's going to do it. Why not me?"

"Human judgment shouldn't be outsourced. We are a long way off that. But all of the steps in between — I think that's fair game."

"Things like Claude Code, Lovable — they are amazing tools, but they are sometimes like the most eager intern that you've ever had on your team."

Want more insights on medtech innovation?

Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND RHYS WILLIAMS ON SOCIAL
Rhys Williams's LinkedIn - https://linkedin.com/in/rhysjwilliams
Orchestrate Website - https://orchestrate.management

Episode Timestamps:
0:00 - Introduction to Rhys Williams and Orchestrate
1:16 - Rhys's journey from medical physics to medtech entrepreneurship
3:57 - Running a Pan-Africa disability innovation accelerator
6:30 - The elevator pitch: what Orchestrate does
8:03 - The $20-50K regulatory clarity problem nobody questions
10:37 - Why paper-based systems persist and why some friction is good
14:12 - Live demo: Orchestrate's regulatory expansion tool
19:46 - The AI-native QMS reveal
24:45 - Meeting users where they are with deep tool integrations
29:48 - The RegTech founder mindset and greenfield opportunity
37:24 - Building teams in the AI agent era
42:07 - The eager intern problem with AI coding tools
47:10 - Regulatory future: AI notified bodies and the banking parallel
55:04 - Hiring for mindset not generation
59:36 - Orchestrate's roadmap: localization partnerships and value chain expansion

I'm joined by Lucas Pianegonda, Founder at Gradical, as we explore sustainable plastics in medtech, from the four forces driving change across a $340 billion industry to practical strategies for choosing better materials without sacrificing patient outcomes.

The Four Forces Driving Sustainable Medtech
→ 49 of the top 100 medtech companies have committed to climate targets through SBTI, representing $340 billion in turnover and 60% of the industry
→ Customer demand is accelerating as hospitals focus on waste reduction, while GPOs like Premier create dedicated sustainability-focused solicitation categories
→ Competitive FOMO compounds the pressure. Once one competitor launches a sustainable product, every company in that space starts their own 2-3 year development cycle
→ European regulations including PPWR and the Green Deal are introducing mandatory eco-design requirements for medical devices

Device Categories Moving Fastest
→ Ophthalmology leads. Cataract surgery is the most prevalent on the planet at 30 million procedures annually, expected to double next decade
→ Endoscopy advancing with Ambu as the poster child, embedding eco-design into corporate strategy
→ Auto-injectors seeing a push from the GLP-1 revolution, alongside lab consumables and complex single-use devices like powered staplers

Single-Use vs. Multi-Use: Not Black and White
→ The spectrum runs from syringes (always single-use) to CT scanners (always reusable). The question is where your device falls on that continuum
→ Ambu's LCA research found 4 out of 5 studies showed single-use endoscopes had a lower environmental footprint than multi-use
→ The more complex the device and the more rare earths involved, the more multi-use makes sense economically and environmentally

The Hilti Model: Subscription-Based Medical Devices
→ Lucas advocates device-as-a-service models that decouple physical production from revenue, comparing surgical staplers to power tools
→ Medtronic's hybrid stapler pairs a durable reusable part with a sterile single-use consumable. Already on market

Remanufacturing: The Controversial Third Path
→ German company Vanguard remanufactures single-use devices by gathering from hospitals, cleaning, testing, re-sterilizing, and reselling as their own legal manufacturer
→ Vanguard gets sued roughly three times a year. The EU is moving toward a unified market for reprocessing single-use devices

Navigating the Sustainable Plastics Landscape
→ The plastic pyramid ranks materials from polypropylene at the bottom to PEEK at the top. Goal: downgrade wherever possible since higher means higher cost and CO2
→ Alternatives include mechanically recycled, chemically recycled, and bio-based drop-ins. Biodegradable plastics cause shelf life problems in 99% of medtech cases
→ Lucas's favorite: polypropylene. Cheap, reliable, manufacturable, already offered in bio-based and chemically recycled variants

Best Quotes:

"Sustainability has degraded into meaning just ecology. Real sustainability means something that can be carried on into the future without detriment."

"If you can make it work with polypropylene, it should be polypropylene."

"My competition has something on the market - I need to do that too. And you know it's going to take two or three years."

Want more insights on medtech innovation?

Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link - https://xo-medtech.circle.so/XO-medtech-pricing-page

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND LUCAS PIANEGONDA ON SOCIAL
Lucas's LinkedIn - https://www.linkedin.com/in/lucas-r-pianegonda-81142b110
Gradical Website - https://www.gradical.ch
Discovery Call - https://calendly.com/lucas-pianegonda-gradical/discovery-call-gradical

Episode Timestamps:
0:00 - Introduction to Lucas Pianegonda and Gradical
8:29 - The Four Forces Driving Sustainable Medtech
16:16 - Device Categories Moving Fastest
19:27 - Single-Use vs. Multi-Use: The Real Tradeoffs
30:34 - Remanufacturing and Vanguard's Model
34:04 - Hybrid Devices and the Subscription Model
41:24 - Sustainable Plastic Alternatives
50:12 - Why Polypropylene Is the Most Underrated Plastic

I'm joined by Brett Jansen, Founder & CEO at HealthTech House, as we explore how AI is transforming go-to-market strategy for medtech startups, why the one-person growth team is becoming reality, and lessons from taking Butterfly Network's handheld ultrasound to market.

From Gym Receptionist to MedTech Growth Leader
→ Brett started as a facilities coordinator at Cerner's gym before executives recruited her into sales, launching a 16-year career across healthcare sales, strategy, and consulting
→ After VP roles at Butterfly Network and CGO at Heartbeat Health, she walked away from W-2 employment entirely. AI gave her the tools to build two successful solo businesses
→ She now hits over $100K per month without sending a single outbound message in 18 months, building entirely through LinkedIn content and inbound demand

AI Turned One Person Into an Entire Commercial Team
→ Brett uses AI to replace what would require a full marketing, copywriting, and social media team, delivering go-to-market services at a fraction of traditional agency costs
→ Her core stack: Claude for deep work and decks, Granola for meeting transcription, GenSpark for rapid content. She built 16 pitch decks on a single flight to JP Morgan Health
→ Claude Opus eliminated her need for a deck designer after it perfectly recreated slides from screenshots

Butterfly Network: Cracking Go-to-Market for Handheld Ultrasound
→ Butterfly was selling $2,000 probes direct-to-consumer when Brett came in to build a B2B enterprise sales motion from scratch
→ The biggest unlock: selling in bulk to medical residency programs with 500-600 students graduating at any given time
→ They productized software alongside the probe, creating named use-case programs with education, wraparound software, and Epic integration

Why Adoption Kills More Deals Than Product Quality
→ Butterfly's biggest enterprise barrier wasn't the tech. It was adoption. Hundreds of probes sent to ED physicians went unused
→ The fix: wrap education into deployment itself, building clinical use case playbooks like FAST protocols for emergency departments
→ The strongest sales rep was a former ultrasound tech doing show-and-tell in hospitals. Clinical credibility beat software sales experience every time

AI Literacy Is the New Competitive Moat
→ Brett teaches the CRTO formula (Context, Role, Task, Output) as the foundation for any AI prompt
→ Most companies wanting AI transformation can't define what good work looks like, meaning any AI deployment is doomed from the start
→ Start with "how do I transform what Monday morning looks like" and identify specific bottlenecks before scaling

The AI Arbitrage Window Is Closing
→ Sales reps who learn AI now will secure their jobs for the next 10 years. Those who don't get left behind
→ Brett used Claude to role-play her speaking panel after Barbara Corcoran. By the time she arrived, she didn't need her note cards

Best Quotes:
"Do I need to outsource this, or can I build this with AI? I'm delegating it out to my army of agents."

"I used Claude to role play with me in the car on the drive down. By the time I got there, I didn't need my note cards. I was cool as a cucumber."

"Those that get curious about AI and start creating their own ecosystem of how to do what they're really good at with AI, you're going to secure your job for the next 10 years."

Want more insights on medtech innovation?
Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link - https://xo-medtech.circle.so/XO-medtech-pricing-page

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND BRETT JANSEN ON SOCIAL
Brett Jansen's LinkedIn - https://www.linkedin.com/in/thebrettjansen/
HealthTech House Website - https://www.healthtechhouse.com

Episode Timestamps:
0:00 - Introduction to Brett Jansen and HealthTech House
3:16 - From Gym Receptionist to Healthcare Sales Leader
5:06 - How AI Enabled Two Solo Businesses Without a W-2
10:22 - One-Size-Fits-All AI Is a Trap
25:04 - Butterfly Network: Building B2B From D2C
31:52 - Adoption Is the Real Enterprise Sales Barrier
42:00 - Career Advice: Using AI to Plan Your Next Move
51:15 - The CRTO Formula for Effective AI Prompting
53:00 - Top 3 AI Tools: Claude, Granola, GenSpark
1:00:37 - Go-to-Market Cohort: 6-Week AI Growth Operating System

I'm joined by Courtney Turich, Global VP of Sales and Marketing at Cooler Heads, as we explore how scalp cooling technology is transforming chemotherapy for cancer patients and the go-to-market challenges of selling devices outside the traditional surgical setting.

From Stryker Sales to Shark Tank
→ Built her career at Stryker as one of few women in her division, then launched Monkey Mat and landed a deal with Mark Cuban and Lori Greiner on Shark Tank
→ The biggest lesson from Shark Tank: the hardest part of entrepreneurship is simply getting started

The Mission Behind Cooler Heads
→ Mechanical cold caps circulate cold fluid to protect hair follicles from chemotherapy, adding 2-3 hours to treatment sessions across pre-cooling, infusion, and post-cooling phases
→ Courtney joined pre-commercialization to build the commercial strategy, helping treat their very first patient after FDA clearance

The Reimbursement Journey: Category 3 to Category 1
→ Transitioned to Category 1 CPT codes in January 2026, shifting from patient-purchased caps to facility-dispensed disposables
→ Hired a VP of Market Access and engaged a third-party agency to push commercial payers to follow Medicare's lead

Selling to Infusion Centers: A Different Playbook
→ The decision maker isn't the oncologist, it's often the cancer center director or lead infusion nurse, with 6-9 month sales cycles even at lower price points
→ Every facility has a different adoption process, making early identification of key decision makers critical

Go-to-Market: Relationships First, Then Scale
→ Leveraged existing relationships to land UPMC, then expanded across their infusion centers while using private centers for faster early traction
→ Patient advocacy became a powerful growth driver, with patients switching facilities to access scalp cooling

Best Quotes:

"Titles mean nothing in the startup world. I really like that cowboy, cowgirl feel of a startup."

"There's no perfect time. You've gotta just jump in and start selling. You could delay your launch over and over again, but you just gotta get that first sell."

"Crawl, walk, run. It is imperative. Get out of the mindset of paralysis by analysis and just get going."

Want more insights on medtech innovation?

Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND COURTNEY TURICH ON SOCIAL
Courtney's LinkedIn - https://www.linkedin.com/in/courtneyturich1/
Bold Moves, Confident Choices Podcast - YouTube
Cooler Heads - https://www.coolerheads.com/

Episode Timestamps:
0:00 - Introduction to Courtney Turich and Cooler Heads
1:12 - Career Journey from Stryker to Shark Tank
3:05 - Startup Mentality and Wearing Multiple Hats
3:24 - Skills That Transfer from Big Corp to Startups
6:25 - How the Medtech Selling Environment Has Evolved
10:11 - What Is Cooler Heads and How Scalp Cooling Works
14:38 - Reimbursement Journey: Category 3 to Category 1
18:47 - Market Access Strategy and Working with Payers
30:52 - The Shark Tank Experience with Monkey Mat
35:32 - Go-to-Market Strategy for Infusion Centers
48:57 - What's Next: Series B and Scaling for Acquisition
49:51 - Biggest Advice for Medtech Founders
55:24 - Leadership, Empathy, and Being Bold

I'm joined by Dan Mazzucco, CEO & Founder of ZSX Medical and Principal at Third Eye Associates, as we explore how he's survived two decades of pivots, FDA battles, and near-death startup experiences building a better way to close surgical wounds - plus an unfiltered look at why women's health innovation is decades behind the rest of medtech.

From ACL Tear to Medical Device Entrepreneur
→ Dan's entire career trajectory changed after tearing his ACL playing ultimate frisbee in college - the idea that you could put a screw in someone's body became the spark for a two-decade medtech career
→ Despite earning a doctorate in biomedical engineering, Dan doesn't draw energy from pure research - he's driven by getting things done and seeing real-world impact on manufacturing costs and patient care
→ Working as a consultant at Exponent, he realized that knocking 3% off manufacturing costs excited him more than novel photon therapy research

Founding ZSX Medical During the Economic Meltdown
→ Dan started ZSX Medical in late 2008 when his previous startup laid everyone off due to the financial crisis, giving him six months notice to figure out what's next
→ He partnered with Eric Ruggart after meeting at networking events, recognizing they had a good team and a good problem even before having a viable technology
→ The company has survived multiple near-death experiences that would have killed most startups - Dan will be sharing those lessons at a conference later this year

The FDA Pivot That Changed Everything
→ FDA told ZSX they'd need to follow 300 women through subsequent pregnancies to validate their C-section closure device - a clinical study costing tens of millions of dollars
→ Rather than building half a bridge, they pivoted to hysterectomy closure after gynecologists consistently said it was a bigger unmet need
→ Their product is an absorbable clothespin-like clip that approximates tissue without piercing it - letting the body heal naturally instead of causing suture-related ischemia and necrosis

When Your Product Fails in the Lab (And What It Actually Means)
→ During cadaver testing, tissue kept pulling out of their clips - a result that felt company-ending until they realized the cadaver tissue was degrading after repeated use, not a product failure
→ Dan shares the story of Active Protective's CEO testing hip airbags that never deployed - a reminder that frustration and failure are the constant companions of device development
→ The key mindset: unexpected results mean you learned something new - now apply that knowledge and move forward

Managing Small Teams When You Can't Pick Your All-Stars
→ On small teams you can't just pick whoever you want - you figure out what each person does really well, what's a stretch, and what's completely out of their range
→ Dan teaches biomedical engineering at Rowan University and uses extended trial periods through teaching and internships to evaluate talent before committing to a full-time hire
→ His best hire came when his CTO overheard a junior student confidently holding her own with three PhDs on a conference call - she now runs their clinical study

The Women's Health Innovation Gap Nobody Talks About
→ The women's health ecosystem is almost diametrically opposed to orthopedics - no track record of successful products, no surgeon profitability, no investor appetite, and a history of disastrous products creating massive headwinds
→ Hospitals treat obstetrics as a loss leader with fancy TVs in delivery rooms - not because they make money, but because mothers choose where the whole family goes for future care
→ From the Dalcon Shield to pelvic meshes, women's health has a legacy of disasters that poisoned the well for every new innovator trying to raise capital or gain FDA trust

Best Quotes:

"Medical device development is all about frustration and failure. If you can't handle frustration and failure, you just need to do something else."

"We're not trying to pierce the tissue. We're just trying to hold it next to the other tissue for two to three weeks. Let the body do the healing."

"Don't chase the largest paycheck. Chase the most learning. The more knowledgeable you are, the more valuable you can be down the road."

"My responsibility behind improving patient lives is caring for the employees entrusted to me."

Want more insights on medtech innovation?

Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND DAN MAZZUCCO ON SOCIAL
Dan's LinkedIn - https://www.linkedin.com/in/danmazzucco/
Dan's Podcast: https://open.spotify.com/show/46gdOqto5XyGL10DQUgozr
ZSX Medical: www.zipstitch.com
3EA: www.3-e-a.com
Rowan University: https://engineering.rowan.edu/faculty_staff/listing/dan-mazzucco.html

Episode Timestamps:
0:00 - Introduction to Dan Mazzucco and His Medtech Journey
1:25 - How Tearing His ACL Sparked a Career in Medical Devices
3:57 - Why Research Doesn't Excite Dan (And What Does)
5:46 - Founding ZSX Medical During the 2008 Economic Crisis
7:47 - The C-Section to Hysterectomy Pivot
10:23 - How FDA's Clinical Pathway Forced a Strategic Shift
12:23 - The Absorbable Clip Technology Explained
15:15 - Perseverance Through Adversity: Cadaver Lab Failures
21:28 - Getting Products Into Real-World Testing Faster
26:42 - Building Versatile Small Teams in Medtech
31:43 - What Dan Looks For When Hiring Early-Career Engineers
41:25 - Dan's Management Philosophy: Employee Care First
47:08 - The Women's Health Innovation Landscape
55:41 - Dan's Plugs: Life Science Insights Podcast, ZSX Medical, Third Eye Associates

I'm joined by Brad Shirley, Founder at DCMS Solutions, as we explore how he helped a physician-inventor's sports med device get acquired by Arthrex, the playbook for navigating strategic partnerships and IP deals, and why most early-stage medtech companies stall before they ever reach a strategic's radar.

From Startup to Arthrex: The HolmesMed Acquisition Playbook
→ How Brad helped Dr. Wendell Holmes take a sports med soft tissue repair device from stalled prototype to a completed deal with Arthrex in roughly two years
→ Dr. Holmes had been getting the dreaded "this is really interesting Dr. Holmes, keep us posted, come back to us in three months" from strategics for years before Brad came on board
→ The missing ingredient wasn't the technology - it was a development roadmap, a clear risk reduction strategy, and someone thinking about the project every single day

Know Your Target: The Research That Closes Deals
→ Before approaching any strategic, study their product portfolio gaps, expiring IP, recent acquisitions, balance sheet strength, and competitive positioning
→ Brad specifically identified mid-market strategics (#4-6 players in the space) as ideal acquirers because they're hungry for differentiated products to move up the rankings
→ Understanding where your technology fills a gap in their portfolio turns a cold pitch into a warm conversation about solving their problem

R vs D: Why Strategics Want Development, Not Research
→ The biggest mistake physician-inventors make is approaching strategics with a research project instead of a development-ready product with clear regulatory and manufacturing pathways
→ Getting to "design freeze" is the critical inflection point that signals to acquirers your technology is real and de-risked enough to evaluate seriously
→ Strategics aren't buying your idea - they're buying a shortened timeline to market with reduced technical and regulatory risk

Slow Down to Speed Up: Iterating With Purpose
→ Brad's philosophy of "slow down to speed up" means every design iteration has a specific purpose and defined outcome rather than open-ended tinkering
→ Rushing prototypes without clear objectives wastes months and burns credibility with potential strategic partners watching your progress
→ The HolmesMed team ran focused iteration cycles that each answered a specific question, dramatically accelerating their path to design freeze

The Fractional Talent Advantage in Early-Stage Medtech
→ Post-COVID medtech layoffs created an incredible pool of experienced quality, regulatory, and R&D professionals available for fractional work
→ Early-stage companies can now access senior talent for quality systems, regulatory strategy, and manufacturing engineering without full-time overhead
→ Brad assembled a fractional team around Dr. Holmes that brought Fortune 500 medtech experience at a startup budget

Physician Founders Need a Quarterback
→ The single biggest gap for physician-inventors is having someone thinking about their project every day - a quarterback coordinating development, regulatory, IP, and deal strategy
→ Most surgeon-inventors have full-time clinical practices and can't dedicate the sustained focus needed to drive a medtech product toward acquisition
→ Brad's role at DCMS Solutions is exactly this: embedding with early-stage medtech teams as a fractional leader who drives the project forward daily

Best Quotes:

"He was getting the dreaded, 'this is really interesting Dr. Holmes, keep us posted, come back to us in three months.' We all know those reactions and what they mean."

"Know your target. If you're going to approach a strategic, you better understand their portfolio, their IP, their balance sheet, and where your technology fills a gap they can't fill themselves."

"I think what most physician founders are missing is someone thinking about this project every single day. That's the quarterback role - someone coordinating all the pieces and driving it forward."

Want more insights on medtech innovation?

Subscribe to the channel so you don't miss hot takes and insider tactics from the trenches of medtech startups.

🤝 Join the #1 network for medtech innovators on the internet. Become a member to accelerate your journey, collaborate and build valuable ventures. Join for free using this link.

Find the perfect vendors for your medtech project for free at MedtechVendors - https://www.medtechvendors.com/

📈 My FREE 5-day course for Medtech Innovators to create successful ventures: https://xomedtech.com/free-course

FIND SPENCER JONES ON SOCIAL
Spencer's LinkedIn - https://www.linkedin.com/in/medtech-innovation/
XO Medtech LinkedIn - https://www.linkedin.com/company/xo-medtech/

FIND BRAD SHIRLEY ON SOCIAL
Brad Shirley's LinkedIn - https://www.linkedin.com/in/bradshirley/
DCMS Solutions Website - https://dcmsolutions.com

Episode Timestamps:
0:00 - Introduction to Brad Shirley and DCMS Solutions
2:02 - The HolmesMed Story: Dr. Wendell Holmes and His Sports Med Device
3:40 - The Dreaded "Come Back in 3 Months" From Strategics
4:28 - R vs D: Why Strategics Want Development-Ready Products
8:00 - Know Your Target: Researching Strategics Before You Pitch
10:00 - Why Warm Intros Beat Cold Outreach Every Time
14:00 - Design Freeze: The Inflection Point That Unlocks Deals
22:00 - Building a Fractional Team With Post-COVID Talent
26:00 - Slow Down to Speed Up: Iterating With Defined Purpose
35:00 - Why Mid-Market Strategics (#4-6 Players) Are Ideal Acquirers
40:00 - Why Physician Founders Need a Full-Time Quarterback
45:00 - New Projects: Autism Eye Tracker and Injectable Hydrogel
55:22 - Deal Timeline: 6-7 Months From First Conversation to Close